24R,25-dihydroxyvitamin D3 promotes the osteoblastic differentiation of human mesenchymal stem cells.

Mol Endocrinol

Geriatric Research, Education, and Clinical Center and Research Service (K.M.C., K.K.A., B.A.R., G.A.H.), Bruce W. Carter Veterans Affairs Medical Center, Miami, Florida 33125; and Departments of Biochemistry and Molecular Biology (K.M.C., G.A.H.), Medicine (B.A.R., G.A.H.), and Neurology (B.A.R.), University of Miami Miller School of Medicine, Miami, Florida 33101.

Published: May 2014

AI Article Synopsis

  • 24R,25-dihydroxyvitamin D3 is crucial for the differentiation of human mesenchymal stem cells (hMSCs) into bone-forming cells, influencing various biological processes.
  • It inhibits hMSC proliferation, reduces the conversion of 25-hydroxyvitamin D3 to the more active 1α,25-dihydroxyvitamin D3, and promotes osteoblastic differentiation through enhanced alkaline phosphatase activity and calcium mineralization.
  • The study highlights a potential regulatory relationship between 24R,25(OH)2D3 and 1α,25(OH)2D3 in the context of bone development, positioning 24R,25(OH)2D3 as

Article Abstract

Although 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] is considered the most biologically active vitamin D3 metabolite, the vitamin D3 prohormone, 25-hydroxyvitamin D3 [25(OH)D3], is metabolized into other forms, including 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3]. Herein we show that 24R,25(OH)2D3 is fundamental for osteoblastic differentiation of human mesenchymal stem cells (hMSCs). Our approach involved analyses of cell proliferation, alkaline phosphatase activity, and pro-osteogenic genes (collagen 1A1, osteocalcin, vitamin D receptor [VDR], vitamin D3-hydroxylating enzymes [cytochrome P450 hydroxylases: CYP2R1, CYP27A1, CYP27B1 and CYP24A1]) and assessment of Ca(2+) mineralization of extracellular matrix. 24R,25(OH)2D3 inhibited hMSC proliferation, decreased 1α-hydroxylase (CYP27B) expression, thereby reducing the ability of hMSCs to convert 25(OH)D3 to 1α,25(OH)2D3, and promoted osteoblastic differentiation through increased alkaline phosphatase activity and Ca(2+) mineralization. 24R,25(OH)2D3 decreased expression of the 1α,25(OH)2D3 receptor, VDR. 24R,25(OH)2D3 but not 1α,25(OH)2D3 induced Ca(2+) mineralization dependent on the absence of the glucocorticoid analog, dexamethasone. To elucidate the mechanism(s) for dexamethasone-independent 1α,25(OH)2D3 inhibition/24R,25(OH)2D3 induction of Ca(2+) mineralization, we demonstrated that 1α,25(OH)2D3 increased whereas 24R,25(OH)2D3 decreased reactive oxygen species (ROS) production. 25(OH)D3 also decreased ROS production, potentially by conversion to 24R,25(OH)2D3. Upon inhibition of the vitamin D3-metabolizing enzymes (cytochrome P450s), 25(OH)D3 increased ROS production, potentially due to its known (low) affinity for VDR. We hypothesize that vitamin D3 actions on osteoblastic differentiation involve a regulatory relationship between 24R,25(OH)2D3 and 1α,25(OH)2D3. These results implicate 24R,25(OH)2D3 as a key player during hMSC maturation and bone development and support the concept that 24R,25(OH)2D3 has a bioactive role in the vitamin D3 endocrine system.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004781PMC
http://dx.doi.org/10.1210/me.2013-1241DOI Listing

Publication Analysis

Top Keywords

osteoblastic differentiation
16
ca2+ mineralization
16
ros production
12
24r25oh2d3
9
differentiation human
8
human mesenchymal
8
mesenchymal stem
8
stem cells
8
alkaline phosphatase
8
phosphatase activity
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!